Arthur Caplan of New York University discusses the issue of allowing expanded access for investigational drugs, often called compassionate use. He presents the case of Josh Hardy, a child with a rare form of kidney cancer whose family pleaded for compassionate use of a drug under development by the pharmaceutical company Chimerix. Josh eventually received the drug, and it helped him recover partially, however such success cases are rare. Today, Right-to-Try laws are gaining in popularity, but according to Caplan they are ineffectual and misguided. Caplan would proposes a system that allows for compassionate use and removes the disincentives for companies to participate, yet is budgetarily limited to a small portion of healthcare spending.

This video is from the Eagleton Institute of Politics at Rutgers University. Visit the original source.
If the video on this page is broken, please report it.
This page has been viewed 1,557 times.

"We have used HealthPolicy.tv to generate ideas about who to invite to campus to speak. There are a lot of great lecturers represented here."

— Jessica F., Chicago, IL